Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products that include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. It also provides spinal implant products comprising cervical, thoracolumbar, and interbody systems for use in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned sales subsidiaries and branches, as well as third-party dealers and distributors in approximately 85 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNYSE:SYK
CUSIP86366710
Phone269-389-2600
Debt
Debt-to-Equity Ratio0.64
Current Ratio1.64
Quick Ratio1.08
Price-To-Earnings
Trailing P/E Ratio26.83
Forward P/E Ratio24.03
P/E Growth2.47
Sales & Book Value
Annual Sales$12.44 billion
Price / Sales5.22
Cash Flow$8.3169 per share
Price / Cash20.89
Book Value$26.67 per share
Price / Book6.51
Profitability
EPS (Most Recent Fiscal Year)$6.49
Net Income$1.02 billion
Net Margins8.00%
Return on Equity25.65%
Return on Assets11.68%
Miscellaneous
Employees33,000
Outstanding Shares373,710,000
Market Cap$64,808.95
Stryker (NYSE:SYK) Frequently Asked Questions
What is Stryker's stock symbol?
Stryker trades on the New York Stock Exchange (NYSE) under the ticker symbol "SYK."
How often does Stryker pay dividends? What is the dividend yield for Stryker?
Stryker announced a quarterly dividend on Thursday, May 3rd. Stockholders of record on Friday, June 29th will be paid a dividend of $0.47 per share on Tuesday, July 31st. This represents a $1.88 dividend on an annualized basis and a dividend yield of 1.08%. The ex-dividend date of this dividend is Thursday, June 28th. View Stryker's Dividend History.
How were Stryker's earnings last quarter?
Stryker Co. (NYSE:SYK) released its earnings results on Thursday, April, 26th. The medical technology company reported $1.68 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $1.60 by $0.08. The medical technology company had revenue of $3.24 billion for the quarter, compared to analysts' expectations of $3.20 billion. Stryker had a net margin of 8.00% and a return on equity of 25.65%. Stryker's quarterly revenue was up 9.7% on a year-over-year basis. During the same period last year, the business earned $1.48 EPS. View Stryker's Earnings History.
When is Stryker's next earnings date?
What guidance has Stryker issued on next quarter's earnings?
Stryker issued an update on its FY18 earnings guidance on Thursday, April, 26th. The company provided EPS guidance of $7.18-$7.25 for the period, compared to the Thomson Reuters consensus estimate of $7.13.
What price target have analysts set for SYK?
22 brokerages have issued 1-year price objectives for Stryker's shares. Their predictions range from $148.00 to $187.00. On average, they expect Stryker's stock price to reach $173.2632 in the next year. This suggests that the stock has a possible downside of 0.3%. View Analyst Ratings for Stryker.
What is the consensus analysts' recommendation for Stryker?
22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stryker in the last year. There are currently 1 sell rating, 7 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
What are Wall Street analysts saying about Stryker stock?
Here are some recent quotes from research analysts about Stryker stock:
- 1. According to Zacks Investment Research, "Stryker’s core Spine segment witnessed double-digit declines in recent times. Supply issues in the Puerto Rico facility and declining gross margin raise concern. The recall of the Oral Care lineup is also discouraging. Foreign currency volatility and reduced demand for healthcare products add to the woes. However, continued demand for the Mako Total Knee Platform and a diversified product portfolio are driving the company’s growth. Stryker’s high domestic and international growth in revenues also buoy optimism. A strong guidance for the second quarter and full year holds promise. Moreover, surging operating margins reflect the company’s bullish prospects. Stryker’s acquisition-driven strategy is expected to boost growth by expanding existing product offerings across all segments, while an enhanced international presence should bolster its global hold. Stryker outperformed the industry in a year’s time." (7/18/2018)
- 2. Cantor Fitzgerald analysts commented, ". This morning (6/11), Journal reported that SYK made a takeover approach of Boston Scientific (Not Covered). Trading on both stocks was halted for a period of time during the day. BSX released an 8-K saying that it was aware of the story, but in accordance with company practice, it does not comment on market rumors or speculation. SYK made similar comment when we reached out directly to them. We view SYK’s potential interest positively, although as somewhat unexpected." (6/13/2018)
Who are some of Stryker's key competitors?
Some companies that are related to Stryker include 3M (MMM), Becton Dickinson and (BDX), Boston Scientific (BSX), FRESENIUS SE &/S (FSNUY), Baxter International (BAX), ABIOMED (ABMD), ResMed (RMD), Teleflex (TFX), Dexcom (DXCM), Hill-Rom (HRC), ICU Medical (ICUI), Globus Medical (GMED), Insulet (PODD), Haemonetics (HAE) and Penumbra (PEN).
Who are Stryker's key executives?
Stryker's management team includes the folowing people:
- Mr. Kevin A. Lobo, Chairman ,CEO & Pres (Age 53)
- Mr. Glenn S. Boehnlein, VP & CFO (Age 56)
- Mr. Lonny J. Carpenter, Group Pres & Adviser to the CEO (Age 56)
- Mr. Timothy J. Scannell, Group Pres of MedSurg & Neurotechnology (Age 53)
- Mr. David K. Floyd, Group Pres of Orthopaedics (Age 57)
Has Stryker been receiving favorable news coverage?
Headlines about SYK stock have been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Stryker earned a news impact score of 0.11 on Accern's scale. They also assigned headlines about the medical technology company an impact score of 48.55 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
Who are Stryker's major shareholders?
Stryker's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Jensen Investment Management Inc. (0.58%), Welch & Forbes LLC (0.15%), Fenimore Asset Management Inc. (0.13%), Confluence Investment Management LLC (0.12%), Bank of Montreal Can (0.08%) and Westpac Banking Corp (0.06%). Company insiders that own Stryker stock include David Floyd, Glenn S Boehnlein, Graham A Mclean, Howard E Cox Jr, Katherine Ann Owen, Kevin Lobo, Lonny J Carpenter, Louise Francesconi, M Kathryn Fink, Roch Doliveux, Ronda E Stryker, Timothy J Scannell, William E Berry Jr and Yin C Becker. View Institutional Ownership Trends for Stryker.
Which institutional investors are selling Stryker stock?
SYK stock was sold by a variety of institutional investors in the last quarter, including Jensen Investment Management Inc., Confluence Investment Management LLC, Calamos Advisors LLC, Westpac Banking Corp, Fenimore Asset Management Inc., Bank of Montreal Can, CenturyLink Investment Management Co and Welch & Forbes LLC. Company insiders that have sold Stryker company stock in the last year include David Floyd, Glenn S Boehnlein, Graham A Mclean, Howard E Cox Jr, Katherine Ann Owen, Kevin Lobo, Lonny J Carpenter, M Kathryn Fink, William E Berry Jr and Yin C Becker. View Insider Buying and Selling for Stryker.
Which institutional investors are buying Stryker stock?
SYK stock was bought by a variety of institutional investors in the last quarter, including Addenda Capital Inc., Mckinley Capital Management LLC Delaware, Meag Munich Ergo Kapitalanlagegesellschaft MBH, Cullinan Associates Inc., Private Capital Advisors Inc., State of Alaska Department of Revenue, Central Bank & Trust Co. and Private Asset Management Inc.. View Insider Buying and Selling for Stryker.
How do I buy shares of Stryker?
Shares of SYK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Stryker's stock price today?
One share of SYK stock can currently be purchased for approximately $173.74.
How big of a company is Stryker?
Stryker has a market capitalization of $64.81 billion and generates $12.44 billion in revenue each year. The medical technology company earns $1.02 billion in net income (profit) each year or $6.49 on an earnings per share basis. Stryker employs 33,000 workers across the globe.
How can I contact Stryker?
Stryker's mailing address is 2825 AIRVIEW BLVD, KALAMAZOO MI, 49002. The medical technology company can be reached via phone at 269-389-2600 or via email at [email protected]
MarketBeat Community Rating for Stryker (NYSE SYK)
MarketBeat's community ratings are surveys of what our community members think about Stryker and other stocks. Vote "Outperform" if you believe SYK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SYK will underperform the S&P 500 over the long term. You may vote once every thirty days.
